Form 4: Harvard Apparatus Regenerative Technology Director Receives Equity Compensation

James E. Shmerling, a non-employee director of Harvard Apparatus Regenerative Technology, Inc., was granted 33,817 stock options with an exercise price of $1.60 per share as part of his compensation.

Summary

• James E. Shmerling, a director at Harvard Apparatus Regenerative Technology, Inc. (HRGN), was granted two tranches of stock options on June 27, 2025.
• The first grant consists of 18,590 stock options, representing the annual equity grant for a non-employee director, with an exercise price of $1.60 per share and an expiration date of June 27, 2035.
• These 18,590 options will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• The second grant consists of 15,227 stock options, granted in lieu of cash compensation otherwise payable to the director, with an exercise price of $1.60 per share and an expiration date of June 27, 2035.
• These 15,227 options will vest in four equal installments on the grant date (June 27, 2025), June 30, 2025, September 30, 2025, and December 31, 2025.
• Following these transactions, James E. Shmerling beneficially owns 33,817 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction related to director compensation. It is neutral in sentiment as it does not indicate any significant positive or negative operational or financial news, but rather a standard corporate governance activity.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders, as the value of their compensation is tied to the company's stock performance.
• Equity compensation is a common practice for non-employee directors, reflecting standard corporate governance practices.

Future Outlook

The stock options granted to the director are subject to future vesting schedules, with the final vesting for the annual equity grant occurring by June 27, 2026, and for the cash-in-lieu grant by December 31, 2025. The options have an expiration date of June 27, 2035.

Management Comments

• The stock option grants represent the annual equity compensation for the reporting person as a non-employee director.
• A portion of the stock options was granted in lieu of cash compensation otherwise payable to the non-employee director.

Industry Context

The granting of stock options to non-employee directors is a standard practice across various industries, including biotechnology and regenerative medicine, to attract and retain qualified board members and align their financial incentives with long-term shareholder value creation. This filing reflects a routine compensation event.

Comparison to Industry Standards

• Equity compensation for non-employee directors, such as stock options, is a widely adopted practice across public companies, including those in the biotechnology sector like Harvard Apparatus Regenerative Technology.
• The structure of annual equity grants and grants in lieu of cash compensation is consistent with common director compensation models seen in companies of similar size and stage, such as smaller biotech firms like Organogenesis Holdings Inc. (ORGO) or MiMedx Group, Inc. (MDXG), which also utilize equity to compensate their non-executive board members.
• The vesting schedules, typically over one to four years, are also standard for director equity awards, ensuring continued engagement and alignment over time.

Stakeholder Impact

• Shareholders: The granting of equity to directors aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Vesting of the 18,590 stock options in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• Vesting of the 15,227 stock options in four equal installments on June 27, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.
• Potential exercise of vested stock options by the reporting person prior to the June 27, 2035 expiration date.

Key Dates

Recommendation

Keywords

Harvard Apparatus Regenerative Technology, HRGN, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, James E. Shmerling